SPARC enters into licensing agreement with Bioprojet

19 Dec 2019 Evaluate

Sun Pharma Advanced Research Company (SPARC) has entered into an agreement with Bioprojet SCR (Bioprojet) to exclusively acquire Bioprojet’s rights to the investigational medicinal product SCD-044. SPARC and Bioprojet co-owned all SCD-044 related IP, developed through a research collaboration targeting Sphingosine -1-Phosphate Receptors (S1PR) to treat various autoimmune disorders.

The acquisition includes full assignment of all patents and patent applications owned or controlled by Bioprojet related to SCD-044. Under the terms of the agreement, Bioprojet is eligible to receive milestones and royalties on net sales of SCD-044

SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Sun Pharma Adv. Res Share Price

134.45 0.70 (0.52%)
30-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 643.75
Indegene 519.25
CMS Info Systems 339.55
Sagility 52.19
Smartworks Coworking 476.45
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×